Publications
Logan AC, Lutzko C, Kohn DB. Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. Current opinion in biotechnology. 2002. PMID: 12459333
Logan AC, Lutzko C, Kohn DB. Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. Current opinion in biotechnology. 2002. PMID: 12459333
Gale M, Blakely CM, Darveau A, Romano PR, Korth MJ, Katze MG. P52rIPK regulates the molecular cochaperone P58IPK to mediate control of the RNA-dependent protein kinase in response to cytoplasmic stress. Biochemistry. 2002. PMID: 12269832
Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002. PMID: 12228201
Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman MA. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2002. PMID: 12393404
Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman MA. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2002. PMID: 12393404
Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman MA. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2002. PMID: 12393404
Bose R, Hwang SW. Income and spending patterns among panhandlers. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2002. PMID: 12240813
Kenny PA, Enver T, Ashworth A. Retroviral vectors for establishing tetracycline-regulated gene expression in an otherwise recalcitrant cell line. BMC molecular biology. 2002. PMID: 12392602
Thall PF, Inoue LY, Martin TG. Adaptive decision making in a lymphocyte infusion trial. Biometrics. 2002. PMID: 12229990
Ko AH, Yuen AR. Clinical outcomes associated with very late relapses in diffuse large cell lymphoma. Volume 43 of Issue 9 Leukemia & lymphoma. 2002. PMID: 12685833
Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B, McCashland T, Sorrell M, Tempero M, Langnas A. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2002. PMID: 12243499
Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002. PMID: 12177096
Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. The Journal of urology. 2002. PMID: 12131305
Locher CP, Witt SA, Ashlock BM, Levy JA. Enhancement of antibody responses to an HIV-2 DNA envelope vaccine using an expression vector containing a constitutive transport element. DNA and cell biology. 2002. PMID: 12215261
Meng MV, Grossfeld GD, Carroll PR, Small EJ. Neoadjuvant strategies for prostate cancer prior to radical prostatectomy. Seminars in urologic oncology. 2002. PMID: 12198633
Small EJ, Harris KA. Secondary hormonal manipulation of prostate cancer. Seminars in urologic oncology. 2002. PMID: 12198635
Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A, Spriggs DR. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002. PMID: 12171876
Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer cell. 2002. PMID: 12204532
Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proceedings of the National Academy of Sciences of the United States of America. 2002. PMID: 12149456